News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
682,990 Results
Type
Article (38959)
Company Profile (276)
Press Release (643755)
Section
Business (203817)
Career Advice (1985)
Deals (35356)
Drug Delivery (84)
Drug Development (80765)
Employer Resources (168)
FDA (16084)
Job Trends (14796)
News (344455)
Policy (32429)
Tag
Academia (2530)
Alliances (49035)
Alzheimer's disease (1212)
Approvals (16002)
Artificial intelligence (114)
Bankruptcy (352)
Best Places to Work (11458)
Biotechnology (196)
Breast cancer (101)
Cancer (886)
Cardiovascular disease (76)
Career advice (1656)
Cell therapy (193)
Clinical research (63887)
Collaboration (317)
Compensation (158)
COVID-19 (2520)
Cystic fibrosis (78)
Data (829)
Diabetes (128)
Diagnostics (6090)
Earnings (84091)
Employer resources (146)
Events (108757)
Executive appointments (239)
FDA (16514)
Funding (286)
Gene therapy (146)
GLP-1 (554)
Government (4316)
Healthcare (18649)
Infectious disease (2593)
Inflammatory bowel disease (101)
Interviews (308)
IPO (16263)
Job creations (3622)
Job search strategy (1415)
Layoffs (407)
Legal (7847)
Lung cancer (154)
Manufacturing (148)
Medical device (13140)
Medtech (13145)
Mergers & acquisitions (19100)
Metabolic disorders (348)
Neuroscience (1450)
NextGen Class of 2024 (6493)
Non-profit (4462)
Northern California (1177)
Obesity (209)
Opinion (175)
Patents (94)
People (56104)
Phase I (19814)
Phase II (28128)
Phase III (21007)
Pipeline (202)
Postmarket research (2553)
Preclinical (8422)
Radiopharmaceuticals (234)
Rare diseases (178)
Real estate (5888)
Regulatory (21425)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1062)
Startups (3560)
United States (11422)
Vaccines (533)
Weight loss (156)
Date
Last 7 days (773)
Last 30 days (2634)
Last 365 days (35546)
2024 (30096)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (186)
Asia (36999)
Australia (6034)
California (2665)
Canada (1163)
China (207)
Colorado (115)
Connecticut (117)
Europe (79193)
Florida (385)
Georgia (98)
Illinois (306)
Indiana (175)
Kansas (95)
Maryland (507)
Massachusetts (2165)
Michigan (142)
Minnesota (246)
New Jersey (805)
New York (824)
North Carolina (656)
Northern California (1177)
Ohio (123)
Pennsylvania (737)
South America (1091)
Southern California (1062)
Texas (372)
Utah (77)
Washington State (315)
682,990 Results for "ceapro inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
Ceapro Inc. today announced financial results and operational highlights for the first quarter ended March 31, 2024.
May 29, 2024
·
10 min read
Business
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
Ceapro Inc. announced operational highlights and financial results for the fourth quarter and full year ended December 31, 2023.
April 29, 2024
·
15 min read
Deals
Aeterna Zentaris and Ceapro Complete Merger Transaction
Aeterna Zentaris Inc. and Ceapro Inc. are pleased to announce the successful completion and closing of their all-stock merger of equals transaction, which was previously announced by Aeterna and Ceapro in their joint press release of December 14, 2023.
June 3, 2024
·
10 min read
Deals
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
Aeterna Zentaris Inc. announces that it has finalized certain details regarding the previously announced merger of equals transaction (the “ Transaction ”) with Ceapro Inc. (“ Ceapro ”).
May 17, 2024
·
11 min read
Deals
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
Aeterna Zentaris Inc. and Ceapro Inc. are pleased to announce that the Court of King’s Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction.
March 28, 2024
·
9 min read
Deals
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
Aeterna Zentaris Inc. and Ceapro Inc. are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction at their respective special meetings.
March 12, 2024
·
11 min read
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
Ceapro Inc., provided an update on its progress across its current business.
February 23, 2024
·
8 min read
Business
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and nine months ended September 30, 2023.
November 29, 2023
·
12 min read
Drug Development
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
Ceapro Inc. (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”) announced today the initiation of its Phase 1 study evaluating its flagship product, avenanthramides, for potential applications in managing conditions related to inflammation.
November 27, 2023
·
5 min read
Drug Development
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
Ceapro Inc.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) today announced the commencement of patient dosing in its Phase 1-2a study evaluating its flagship product, avenanthramides, for potential applications in managing conditions related to inflammation.
December 13, 2023
·
4 min read
1 of 68,299
Next